independence blue cross glp 1 coverage Cross, a major #insurance company, joins a growing number of firms not covering GLP-1 drugs for #weightloss, blaming exorbitant costs. Doctors say the drugs that treat diabetes and obesity are Excellus BlueCross BlueShield is clarifying

This is mostly an administrative change to contracts and rates, White wrote in an email, noting the drugs would be struck from the preferred drug list

Failure of GLP-1 (7-36) amide to affect glycogenesis in rat skeletal muscle

If youve ever wondered whether a natural supplement could actually do what it promises without side effects, crash diets, or synthetic shortcuts, now you know

Elife 2014;3:e02523

Eylea (aflibercept) Disease area(s): Ophthalmology Manufacturer(s): Regeneron/Bayer 2024 Sales (USD): $9.55 billion Why it sold so well: Eylea registered strong sales in 2024, driven by the introduction of Eylea HD, which received FDA approval in 2023 and is an 8 mg formulation offering extended dosing intervals for retinal diseases